ALFA Filings
Every announcement, straight from the exchange
Every Glenmark Pharmaceuticals regulatory approval announcement on NSE and BSE, newest first, each with its own page.
Time
2 announcements
Glenmark received U.S. FDA approval to expand the use of its RYALTRIS nasal spray to pediatric patients aged 6 to less than 12 years.
Glenmark Pharmaceuticals received final U.S. FDA approval for Progesterone Vaginal Inserts, 100 mg. The product targets a market with annual sales of approximately ₹544.64 Crore ($59.2 million). This approval strengthens Glenmark's women's healthcare portfolio in the U.S. market.